CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation.

about

CDK4/6 inhibition in breast cancer: current practice and future directions CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

P2860

Q57109486-221991D7-D93C-46EB-AAB9-BC5510BD50C0 Q57176702-6AAEFBBA-82F1-4D20-9C63-4C0548C550D1

P2860

CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation.

Item

http://www.wikidata.org/entity/Q47443248

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation.

@en

CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation.

@nl

type

Item

label

CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation.

@en

CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation.

@nl

prefLabel

CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation.

@en

CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation.

@nl

P1476

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

@en

P2093

Amanda J Rode

http://www.w3.org/2001/XMLSchema#string

Amir R Aref

http://www.w3.org/2001/XMLSchema#string

Annan Yang

http://www.w3.org/2001/XMLSchema#string

Ashley A Merlino

http://www.w3.org/2001/XMLSchema#string

Chensheng W Zhou

http://www.w3.org/2001/XMLSchema#string

Cloud P Paweletz

http://www.w3.org/2001/XMLSchema#string

David A Barbie

http://www.w3.org/2001/XMLSchema#string

Elena Ivanova

http://www.w3.org/2001/XMLSchema#string

Eric Haines

http://www.w3.org/2001/XMLSchema#string

Eric S Wang

http://www.w3.org/2001/XMLSchema#string

P2860

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Acquired and intrinsic resistance in cancer immunotherapy

A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

The blockade of immune checkpoints in cancer immunotherapy

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Identification of amino acid residues and protein kinases involved in the regulation of NFATc subcellular localization

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

P304

216-233

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-17-0915

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29101163

http://www.w3.org/2001/XMLSchema#string

P932

5809273

http://www.w3.org/2001/XMLSchema#string

CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation.

about

P2860

P2860

CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932